BioXcel Therapeutics (BTAI) Revenue & Revenue Breakdown
BioXcel Therapeutics Revenue Highlights
Latest Revenue (Y)
$2.27M
Latest Revenue (Q)
$168.00K
BioXcel Therapeutics Revenue by Period
BioXcel Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2024-12-31 | $2.27M | 64.20% |
2023-12-31 | $1.38M | 268.00% |
2022-12-31 | $375.00K | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2016-12-31 | - | 100.00% |
2015-12-31 | - | - |
BioXcel Therapeutics generated $2.27M in revenue during NA 2024, up 64.20% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
BioXcel Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2025-03-31 | $168.00K | -54.10% |
2024-12-31 | $366.00K | 71.03% |
2024-09-30 | $214.00K | -80.62% |
2024-06-30 | $1.10M | 89.69% |
2024-03-31 | $582.00K | 54.79% |
2023-12-31 | $376.00K | 10.26% |
2023-09-30 | $341.00K | -25.38% |
2023-06-30 | $457.00K | 121.84% |
2023-03-31 | $206.00K | -13.45% |
2022-12-31 | $238.00K | 73.72% |
2022-09-30 | $137.00K | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | -100.00% |
2020-12-31 | $0.02 | 100.00% |
2020-09-30 | $0.01 | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2017-09-30 | - | 100.00% |
2017-06-30 | - | 100.00% |
2017-03-31 | - | - |
BioXcel Therapeutics generated $168.00K in revenue during Q1 2025, up -54.10% compared to the previous quarter, and up 44.68% compared to the same period a year ago.
BioXcel Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
EXEL | Exelixis | $2.17B | $566.75M |
APLS | Apellis Pharmaceuticals | $709.95M | $212.53M |
MDGL | Madrigal Pharmaceuticals | $180.13M | $137.25M |
DAWN | Day One Biopharmaceuticals | $131.16M | $29.21M |
AMLX | Amylyx Pharmaceuticals | $87.37M | $-665.00K |
XFOR | X4 Pharmaceuticals | $2.56M | $28.81M |
BTAI | BioXcel Therapeutics | $2.27M | $168.00K |
VKTX | Viking Therapeutics | - | - |
TGTX | TG Therapeutics | - | $108.19M |
HEPA | Hepion Pharmaceuticals | - | - |
ABOS | Acumen Pharmaceuticals | - | - |
INZY | Inozyme Pharma | - | - |
TERN | Terns Pharmaceuticals | - | - |
ELEV | Elevation Oncology | - | - |
MREO | Mereo BioPharma Group | - | - |